Deubiquitinating enzymes as oncotargets by McClurg, Urszula L & Robson, Craig N
Oncotarget9657www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 6, No. 12
Deubiquitinating enzymes as oncotargets
Urszula L. McClurg1 and Craig N. Robson1
1 Solid Tumour Target Discovery Laboratory, Newcastle Cancer Centre, Northern Institute for Cancer Research, Medical 
School, Newcastle University, Newcastle upon Tyne, UK
Correspondence to: Craig N. Robson, email: craig.robson@ncl.ac.uk
Keywords: deubiquitination, DUBs, cancer, epigenetics, chromatin, androgen receptor, histones
Received: March 09, 2015 Accepted: April 08, 2015 Published: April 23, 2015
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
AbstrAct
Carcinogenesis is a complex process tightly regulated at multiple levels by post-
translational modifications. Epigenetics plays a major role in cancer development, 
all stable changes to the gene expression process that are not a result of a direct 
change in the DNA code are described as epigenetics. Epigenetic processes are 
regulated by post-translational modifications including ubiquitination which can 
directly affect either histones or transcription factors or may target their co-factors 
and interacting partners exerting an indirect effect. Deubiquitination of these target 
proteins is equally important and alterations in this pathway can also lead to cancer 
development, progression and metastasis. Only the correct, unaltered balance 
between ubiquitination and deubiquitination ensures healthy cellular homeostasis. In 
this review we focus on the role of deubiquitinating (DUB) enzymes in various aspects 
of epigenetics including the regulation of transcription factors, histone modifications, 
DNA damage repair pathways and cell cycle regulation. We discuss the impact of 
those processes on tumourigenesis and potential therapeutic applications of DUBs 
for cancer treatment.
IntroductIon
Ubiquitination is one of the most important 
post-translation modifications (PTMs) responsible for 
regulating the stability and activity of modified proteins. 
For the ubiquitin molecule to be attached to its target 
protein it initially has to be activated by an E1 enzyme 
during an ATP-dependent reaction, which is followed by 
conjugation of ubiquitin by an E2 class enzyme allowing 
E3 ubiquitin ligase to ubiquitinate target proteins directly 
or indirectly [1], [2], [3] . 
The consequences of ubiquitination depend on the 
type of chains formed during the process [4]. Proteins can 
be mono-, multi-mono- or poly-ubiquitinated. Ubiquitin 
contains seven lysine (K) residues with poly-ubiquitin 
chains linked through the K6, K11, K27, K29, K33, K48 
and K63 residues. Mono-ubiquitination and K63 poly-
ubiquitination have been linked to regulating protein 
activity [5]. K6, K11, K29 and K48 poly-ubiquitin chains 
control protein stability with K6 and K48 chains targeting 
proteins for proteosomal degradation, K11 is involved in 
endoplasmic reticulum mediated degradation pathways 
and control of cell cycle progression and K29 in regulating 
lysosomal degradation of proteins [6]. The role of K27 
and K33 poly-ubiquitination is less understood however, 
they have been linked to innate immunity and immune 
responses.
deubiquitinating enzymes (dubs)
Just as every action provokes a reaction all of the 
major post-translational modifications can be reversed. 
Enzymes that reverse PTMs are equally important 
to normal homeostasis as those that initially modify 
proteins. Protein ubiquitination by the E3 ligases can be 
reversed by deubiquitinating enzymes [7]. DUBs can be 
divided into five families; ubiquitin carboxy - terminal 
hydrolases (UCH), ubiquitin specific proteases (Usp), 
Otubain/Ovarian tumour - domain containing proteins 
(OTU), Machado - Joseph Domain (Josephin domain) 
- containing proteins (MJD) and Jab1/MPN domain 
associated metalloisopeptidase domain proteins. UCH, 
Usp, OUT and MJD proteins are all thiol proteases 
containing an active site cysteine which serves as a 
nucleophile facilitating the attack on lysine-glycine 
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isopeptide bonds of ubiquitinated proteins. Jab1/MPN 
domain associated metalloisopeptidase domain proteins 
differ from the other DUB classes as they utilise a JAMM 
zinc metalloproteinase domain to break the bond between 
their target proteins and ubiquitin. 
With increased appreciation for the critical 
importance of ubiquitination in cellular processes, DUBs 
role in health and disease is becoming a new focus of 
scientific research. Recent advances in the field uncovered 
a growing number of DUB substrates. DUBs control the 
stability and activity of multiple proteins crucial in cellular 
proliferation and survival including p53 - the guardian 
of the genome [8], [9], MDM2 [10], androgen receptor 
(AR) [11], [12], histones [13], [14], PHLPP and PHLPPL 
Akt phosphatases [15], [16], [17], Notch [18], NF-κB 
[19], [20], β-catenin [21], [22] and many more. It is now 
understood that a tight balance between ubiquitination 
and deubiquitination is required for cellular survival 
underlying the equal importance of E3s and DUBs.
Epigenetics and dubs in cancer
All stable, long-term alterations to the transcriptional 
potential of the cells that are not caused by direct changes 
to the DNA sequence itself and can be passed to daughter 
cells are referred to as epigenetics. These changes include 
DNA methylation, histone modifications and alterations 
to the activity of repressors and transcription factors. All 
of these processes result in altered transcriptome and 
affect cellular growth, survival and homeostasis; as such 
epigenetics play a crucial role in cancer development 
and progression [23]. DUBs can regulate all levels of 
epigenetic changes, by deubiquitinating proteins and 
changing their activity and / or stability DUBs control the 
levels of methylases and demethylases, histone proteins 
and their binding partners, repressors and transcription 
factors (Figure 1). DUBs can have both activating and 
repressing effects on gene transcription depending on 
their target proteins and the type of ubiquitin chain that 
is being removed. Additionally, DUBs can alter ubiquitin 
chains rather than remove them completely by for example 
deubiquitinating K48-linked chains and leaving the target 
protein in a mono-ubiquitinated state which results in 
altered protein fate. In this review we will focus on the role 
of DUBs in epigenetics and resulting cancer development. 
We will also review the potential therapeutic aspects of 
targeting DUBs to affect cellular epigenetics.
Figure 1: role of deubiquitinating enzymes in different aspects of cancer epigenetic regulation.
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rEgulAtIon oF EpIgEnEtIcs by 
dEubIquItInAtIon
regulation of transcription factors
Gene expression is controlled by transcription 
factors that directly bind to DNA. Transcription factors 
act in complexes with other proteins and DUBs can 
affect their activity by deubiquitinating transcription 
factors directly or by targeting their binding partners and 
altering the stoichiometry of the complex. Usp12 activity 
towards the androgen receptor (AR) is an example of 
direct transcription factor deubiquitination [12]. AR is 
a member of the nuclear receptor superfamily and plays 
a key role in the transcriptional regulation of numerous 
genes important in the development of both normal and 
malignant prostate. AR deregulation is the key feature of 
prostate cancer (PC) development. Usp12 was reported 
to deubiquitinate the AR resulting in its increased protein 
stability and transcriptional activity [12]. As a result Usp12 
promotes PC development with protein levels increased 
in PC patients compared to benign controls. However, 
AR has multiple ubiquitination sites and it is targeted by 
a variety of E3s, as a result AR deubiquitination doesn’t 
always promote transcription. Usp26 can directly bind 
and deubiquitinate AR, acting as a co-regulator of the AR 
by reversing AR activation and degradation by MDM2 
ubiquitination depending on cellular context highlighting 
the complexity of post-translational regulation [11]. 
Similarly, Estrogen Receptor (ER) can also be regulated 
by deubiquitination, OTUB1 has been identified to target 
ER-alpha affecting ER target gene transcription and 
stabilising its protein levels on chromatin [24].
Sometimes it is not clear if DUBs control 
transcription factors via direct deubiquitination or if their 
regulation of the transcriptome is more via effects exerted 
on histones that cause a signalling cascade affecting the 
transcription factors. This is the case for Usp10, it was 
initially reported to directly regulate p53 and AR by 
deubiquitinating them and acting as a co-activator [25]. 
However, more recent reports indicate that the effects on 
AR might be indirect via Usp10 activity towards mono-
ubiquitinated histone H2A.Z [14]. As a result of Usp10’s 
role in the regulation of histones and p53 it is frequently 
overexpressed in breast and brain cancer patients where 
its levels correlate with survival. In prostate cancer, with 
increasing grade of disease, the cellular localisation of 
Usp10 changes with expression becoming predominantly 
nuclear allowing for higher activity towards H2A.Z. 
Similarly MYSM-1 has been reported to indirectly 
regulate the AR. MYSM-1 can activate transcription of 
AR target genes via its involvement with p300 affecting 
histone acetylation and deubiquitination and binding of H1 
to the nucleosome [26].
P53 is a crucial tumour suppressor acting as 
a transcription factor responsible for regulating the 
expression of multiple genes associated with stress 
responses, cellular survival, growth and homeostasis 
[27], [28], [29]. P53 can be directly deubiquitinated by 
Usp42 which reverses its ubiquitination by MDM2 [9]. 
Usp42 forms a direct complex with p53 and controls 
its activation in response to cellular stress; as a result 
it regulates p53-dependent transcription and cell cycle 
arrest. Usp7 is another DUB important for p53 activity 
[8]. Usp7 regulates the polycomb complex and factors 
associated with transcription including MDM2, p53 and 
FOXO. Usp7 directly deubiquitinates and stabilises p53, 
it is also necessary for p53 stabilisation by the tumour 
suppressor ING1 [30]. Additionally, independently of its 
deubiquitinase activity the DUB Usp7 regulates sequence 
specific RNA binding of the core domain of p53 thereby 
stimulating its transcriptional activity and expression of 
p21 [31]. Consequently, Usp7 inhibition was reported to 
inhibit cancer cell growth and increase apoptosis.
Some DUBs can control p53 stability independently 
of their enzymatic activity. One such example is OTUB1 
which can inhibit UbcH5. UbcH5 is an MDM2 cognate 
ubiquitin-conjugating enzyme (E2), as a result of its 
inhibition p53 ubiquitination is abrogated leading to its 
increased stability and activity [32], [33]. Through binding 
to E2 enzyme Ubc13, OTUB1 also regulates the K63 
ubiquitination of chromatin induced by DNA damage [34].
GATA3 serves as another example of a transcription 
factor regulated by deubiquitination. GATA3 is a master 
regulator of T helper cells (Th2) cell differentiation and 
function; it controls early T cell development and is one 
of only 3 genes mutated in over 10% of breast cancers 
as it plays a key role in mammary gland development 
[35], [36]. Recent reports demonstrate that GATA3 
can be deubiquitinated by Usp21 which rescues it from 
proteosomal degradation and stabilises GATA3 protein 
levels [37]. This results in increased transcriptional 
activity of GATA3 and highlights the role of Usp21 in 
immune responses with Usp21 protein upregulated in 
regulatory T cells (Tregs) from asthma patients, however 
the role of this interaction in carcinogenesis still remains 
to be established. 
Both canonical and non-canonical Wnt signalling 
pathways are also regulated by deubiquitination. Recent 
reports identified proteasome associated DUB Usp14 as 
an oncogene and a positive regulator of Wnt signalling via 
deubiquitination of Dishevelled (Dvl) [38]. Depletion of 
Usp14 attenuated downstream Wnt signalling which was 
further evidenced when correlation between the levels of 
Usp14 and β-catenin in colon tissues was observed. Usp14 
was also up regulated in non-small cell lung carcinoma 
where high levels correlated with decreased survival and 
poor prognosis [39]. This was attributed to the oncogenic 
properties of Usp14 with silencing causing cell cycle 
arrest as a consequence of β-catenin degradation.
Oncotarget9660www.impactjournals.com/oncotarget
An additional level of control of transcriptional 
activity mediated by the nuclear receptors is provided by 
the SAGA (Spt-Ada-Gcn5-acetyl 1 transferase) histone 
acetyltransferase (HAT) complex. In addition to HAT 
activity, SAGA has deubiquitinating activity, which is 
required for the transcriptional activity of nuclear receptors 
with Usp22 being the active DUB subunit of SAGA 
that removes ubiquitin from the histones H2A and H2B 
[40]. As SAGA is a chromatin modifying transcription 
coactivator complex which regulates the expression of 
genes related to tumourigenicity and proliferation its 
levels predict treatment failure and are also used as a 
marker of recurrence, metastasis and resistance to therapy 
with levels significantly increased in cancers, including 
colorectal cancer [41], [42].
regulation of histones
Mono-ubiquitination of histone H2A is one of 
the key histone modifications, it is associated with 
transcriptional repression by the polycomb group 
proteins and maintenance of the genome integrity. H2A 
is mono-ubiquitinated at K119 and it is estimated that 
between five and fifteen percent of the H2A fraction is 
mono-ubiquitinated at any one time compared to only 
one percent of H2B. As previously discussed, Usp10 can 
deubiqutinate the mono-ubiquitinated H2A.Z variant of 
H2A which results in increased AR activity [14]. However, 
H2A can also be deubiquitinated by MYSM1 (2A-DUB) 
[26] and UbpM (Usp16) in a way that is independent 
of its phosphorylation by CDK1 [43], [44]. UbpM 
specifically deubiquitinates histone H2A, but not H2B. 
This deubiquitination is required for dephosphorylation of 
histone H3 on S10 resulting in chromosome segregation 
during the mitotic entry. As a result, UbpM silencing 
decreases cell growth due to defects in mitosis. UbpM 
similarly controls Hox gene expression via regulation 
of H2A ubiquitination status. Ubiquitination of H2A 
is known to contribute to the embryonic stem cell 
(ESC) pluripotency by repressing lineage-specific gene 
expression [45]. It has been reported that deubiquitination 
of H2A by UbpM controls gene expression in ESCs with 
UbpM binding to the promoter regions of multiple genes 
in ESCs and regulating the H2A ubiquitination levels. 
It is now established that UbpM is required for ESCs to 
differentiate, as in its absence ubiquitinated H2A mediates 
repression of lineage-specific genes expression abrogating 
cellular differentiation [45].
Histone ubiquitination plays a vital role in both 
DNA damage response and repair pathways (Table 1). 
Increased mono-ubiquitination of H2A, H2B, H3 and H4 
has been previously observed upon DNA damage. During 
the early DNA damage response, DNA-PK, ATM and ATR 
kinases phosphorylate a fraction of the H2AX variant of 
H2A, which is commonly referred to as γH2AX [46], 
[47]. RNF168 is an E3 ligase that ubiquitinates histones 
H2A and γH2AX during the DNA damage response [48], 
this ubiquitination can be reversed by Usp3 [49]. Usp3 
associates with chromatin and deubiquitinates H2A 
at K13 and K15 and γH2AX at K118 and K119. As a 
result Usp3 overexpression has been shown to impair the 
accumulation of the BRCA1 and 53BP1 repair factors at 
the DNA damage sites in response to DNA damage and 
to counteract the activity of RNF168. Consistent with 
these findings, Usp3 ablation caused accumulation of 
DNA breaks and activation of DNA damage checkpoint 
pathways. This pathway can also be reversed by other 
DUBs, including Usp21 [50], OTUB1, Usp29 and 
Usp44 [51]. Both Usp44 and Usp29 deubiquitinate H2A 
with USP44 being recruited to the RNF168-generated 
ubiquitination products at double stranded break sites [51].
table 1: role of dubs in histone deubiquitination and the cellular consequences
dub dub Family Histone substrates cellular processes
Usp3 Usp H2A and H2B DNA repair and cell cycle progression
Usp7 Usp H2A and H2B Gene expression, protein stability, cell cycle progression and proliferation
Usp10 Usp H2A DNA repair and transcription
Usp12 Usp H2A and H2B Transcription
UbpM 
(Usp16) Usp H2A
DNA repair, cell cycle progression, differentiation and 
proliferation
Usp21 Usp H2A Gene expression and DNA repair
Usp22 Usp H2A and H2B Gene expression, protein stability, proliferation and cell cycle progression
Usp29 Usp H2A DNA repair and transcription
Usp44 Usp H2A DNA repair, cell cycle progression and differentiation
Usp46 Usp H2A and H2B Transcription
Usp49 Usp H2B Gene expression and pre-mRNA processing
MYSM1 JAMM H2A Transcription, haematopoiesis
OTUB1 OTU H2A DNA repair
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Ubiquitination of both H2A and H2B is equally 
important for maintaining cellular homeostasis and there 
are DUBs that specifically target histone H2B, including 
Usp49 [52] and Usp42 [53]. H2B ubiquitination regulates 
H3K4 and H3K79 methylation and impacts on the 
chromatin structure [52]. Usp49 in complex with RVB1 
and SUG1 yeast homologues deubiquitinates H2B, this 
modification is required for efficient co-transcriptional 
splicing of a large set of exons. Silencing Usp49 induces 
relatively small changes in gene expression, however 
alterations in H2B ubiquitination levels caused by Usp49 
regulate U1A and U2B association with chromatin and 
binding to nascent pre-mRNA. Consequently, Usp49 plays 
a crucial role in co-transcriptional pre-mRNA processing 
[52]. H2B ubiquitination can additionally be reversed by 
Usp7 resulting in epigenetic silencing of homeotic genes 
[54]. 
Some DUBs are not as specific and have the 
ability to deubiquitinate both histones H2A and H2B, for 
example the closely related family of DUBs comprising 
Usp1, Usp12 and Usp46. All three DUBs require 
Uaf-1 (WDR48) for their enzymatic activity [55] and 
additionally Usp12 and Usp46, but not Usp1, activity is 
further enhanced by binding to WDR20 [56]. Usp12 and 
Usp46 deubiquitinate both H2A and H2B and Uaf-1 is 
required for this reaction [13]. Usp22 can also reverse 
the polycomb complex mediated ubiquitination of H2A 
and H2B causing multiple changes in gene expression 
profiles including transcriptional activation of MDM2 
and Hox [57], [58]. Recent reports however, indicate that 
even though Usp22 is active towards both H2A and H2B 
it preferentially targets H2B for which it is one of the main 
DUBs.
cell cycle regulation and dnA damage response
In normal cells most genes have an epigenetically 
stable transcriptional status. However, some genes are 
an exception to this rule as their sole purpose is to be 
responsive to the outside stimuli including growth factors 
and cellular contact. Those genes are most susceptible to 
epigenetic changes and their expression is rapidly affected 
by them. Dysregulation of epigenetics might result in 
altered expression of these genes leading to cellular 
transformation and malignancy. As a result, impact of 
DUBs on cell cycle regulation and DNA damage repair 
pathways deserves specific attention. The human genome 
is continuously challenged by both endogenous and 
exogenous insults potentially damaging the DNA which 
can result in various types of damage including double 
and single strand breaks, oxidative lesions and pyrimidine 
dimers. Cells have developed multiple ways to counteract 
and repair the DNA damage known as the DNA damage 
response pathways. These responses can be divided 
into two main groups; cell-cycle checkpoint activation 
and DNA repair. Both of these mechanisms are tightly 
controlled by chromatin remodelling and epigenetics.
As discussed in previous sections multiple DUBs 
affect cell cycle indirectly by regulating transcription 
factors that control cell cycle progression, including the 
AR and p53, and by modulating histones. However, some 
DUBs regulate cell cycle in a much more direct fashion. 
DUBs can regulate cell cycle progression by controlling 
the G2/M checkpoint. Specifically both Usp50 and UbpM 
contribute towards this process. Usp50, even though it is 
catalytically inactive, plays a role in cell cycle progression. 
It associates with Hsp90 and controls Wee1 stability via 
an Hsp90-dependent mechanism. Usp50 consequently 
functions as a negative regulator of the G2/M checkpoint 
[59]. UbpM regulates the same checkpoint but via a 
different mechanism. Following S552 phosphorylation 
UbpM translocates to the nucleus and regulates the cell 
cycle G2/M phase progression and cell proliferation 
[44]. Additionally, Usp22 directly deubiquitinates TRF1 
(TBP(TATA box-binding protein)-related factor 1) to 
regulate the transcription of cell cycle and apoptosis 
genes [60] and inhibits the transcriptional activity of p53 
by deubiquitinating SIRT1 histone deacetylase [61] and by 
regulating MDMX stability [62]. 
Usp1 is a key protein involved in the DNA damage 
response. Indeed inhibition of the Usp1-Uaf-1 complex 
sensitises cells to chemotherapy. Usp1 counteracts the 
mono-ubiquitination of PCNA which prevents recruitment 
of low fidelity DNA polymerases in the absence of DNA 
damage [63]. It is also involved in double strand DNA 
break repair through the homologous recombination 
pathway. Additionally, Usp1 deubiquitinates and 
stabilises ID (Inhibitor of DNA binding) proteins 1, 
2 and 3, as ID can inhibit differentiation this preserves 
the undifferentiated state of cells [64]. Usp1 modulates 
DNA replication, polymerase choice and DNA repair by 
PCNA and as a result Usp1 knock-out mice are genetically 
unstable and hypersensitive to DNA damage [65], [66]. 
Usp10 is involved in DNA damage response control 
via regulation of the p53 protein. Upon DNA damage, 
Usp10 is phosphorylated which is essential for Usp10 to 
relocate to the nucleus, allowing it to stabilise p53 [67]. 
The DNA damage response is also regulated by the Chk2-
p53-PUMA pathway in response to double strand breaks 
in vivo. This process is tightly controlled by Usp28 which 
is necessary to stabilise Chk2 and 53BP1 in response to 
DNA damage and is required for DNA damage induced 
apoptosis [68]. Usp28 is found to be recruited to double 
strand breaks and this is dependent on the 53BP1 protein. 
regulation of deubiquitinating enzyme activity
Activity and stability of multiple DUBs is regulated 
by posttranslational modifications and interactions with 
other proteins. Commonly enzymes are regulated by 
phosphorylation, this is also frequent amongst DUBs. To 
allow its activity towards p53, the Usp10 protein needs to 
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be phosphorylated at T42 and S337 by ATM, this occurs 
as a result of DNA damage and stabilises Usp10 allowing 
it to translocate to the nucleus and deubiquitinate p53 
[67]. Interestingly in prostate cancer with increased cancer 
grade and metastasis the expression of Usp10 becomes 
predominantly nuclear which could possibly be associated 
with elevated DNA damage. Phosphorylation of Usp10 
by ATM is also required for Usp10 antioxidant activity in 
stress granules [69]. Phosphorylation of UbpM at Ser552 
by cyclin-dependent kinase 1 (CDK1) is also needed for 
its translocation to the nucleus and regulation of the cell 
cycle G2/M phase progression and cell proliferation but, 
this phosphorylation is not required for its deubiquitinase 
activity, substrate specificity and regulation of gene 
expression [44]. Similarly, Usp7 short isoform (Usp7S) 
can be phosphorylated by CK2 at S18 leading to its 
protein stabilisation which subsequently increases the pool 
of MDM2 and decreases the levels of p53 protein [70]. 
This is reversed upon irradiation by an ATM dependant 
phosphatase PPM1G [70]. DUBs can play a role in 
infection and immunity and their activity can be regulated 
by bacterial kinases. During Yersinia infection OTUB1 
can be phosphorylated by a bacterial kinase YpkA which 
modulates cellular susceptibility to Yersinia invasion [71].
Many of DUB phosphorylation sites are highly 
conserved throughout evolution. Yeast homologue of 
Usp12 (Ubp9) has been shown to be phosphorylated and 
this phosphorylation was lost upon deletion of both of its 
co-factors Uaf-1 and WDR20 highlighting its potential 
role in enzymatic activity [72]. Similarly close family 
member of Usp12, Usp1 is also phosphorylated at S313 
by CDK1 during mitosis, this modification is required 
for its interaction with Uaf-1 as it lies within the Uaf-1 
binding region (amino acids 235-408). Consequently, it 
is also a pre-requisite for Usp1 DUB activity as complex 
formation with Uaf-1 is required [73], [74]. Conversely 
phosphorylation at S42 and S67 have not been attributed 
any physiological roles to date [73]. S313 of Usp1 lies 
within both the consensus sequence for CDKs and 
also Usp1s region 307-330 responsible for APC/C 
cdh1 mediated Usp1 degradation during G1 phase. 
Consequently S313 phosphorylation plays a crucial role 
in maintaining protein stability during mitosis as Usp1 
is ubiquitinated during G1 by APC/C cdh1 leading to 
its proteosomal degradation. Usp1 can be additionally 
stabilised by CAPNS1 which activates Cdk5 resulting 
in inhibition of cdh1 subsequently inhibiting Usp1 
degradation [75]. 
Frequently the activity of deubiquitinating enzymes 
is regulated by interactions with various binding partners. 
TRAF2 can bind to Usp2a which inhibits its effect on K48 
but not K63 linked poly-ubiquitin chains, consequently 
the ratio between TRAF2 and Usp2a determines cells 
sensitivity to cell death [76]. Usp10, alongside Usp13, 
is regulated by binding to Beclin-1 which affects their 
protein stability, activity and subsequent deubiquitination 
of target proteins [77]. Usp22 activity is regulated by 
histone deacetylases, their inhibition abrogates the binding 
of RNA Polymerase II to Usp22 promoter supressing its 
transcription [78] .
DUB protein stability has a crucial role in regulating 
enzymatic activity; some DUBs can auto-regulate 
themselves others are ubiquitinated/SUMOylated. For 
example, Usp7 is activated by its own C-terminal domain 
[79]. Conversely, Usp1 has the ability to auto-cleave 
itself at a di-glycine motif leading to its degradation [80]. 
OTUB1 is regulated by mono-ubiquitination at K59 and 
K109 which is required for it to inhibit the E2 UhcH5 
resulting in MDM2 inhibition and p53 activation [33]. 
Binding of OTUB1 and E2 enzymes, including UbcH5 
and Ubc13, also regulates OTUB1 enzymatic activity 
towards K48 ubiquitin chains [81]. Usp28 on the other 
hand can be regulated by SUMOylation at the N-terminal 
domain, this has a negative effect on its deubiquitinase 
activity [82]. 
Splicing can also play a role in the regulation 
of DUBs activity and cellular localisation. Both Usp7 
and Usp21 have been reported to undergo alternative 
splicing. Usp21 short variant lacks the nuclear export 
sequence (NES) and as a result localises predominantly 
in the nucleus however, that has no major effect on its 
enzymatic activity as both full length and variant Usp21 
affect H2A ubiquitination to a comparable degree in vitro 
but variant was observed to be more active in vivo due to 
its localisation [83].
targeting dubs
DUBs are key enzymes which regulate cellular 
growth, survival and homeostasis through multiple 
pathways including epigenetics, as such aberrations in 
DUB signalling and activity can play crucial roles in 
cancer development, progression and metastasis. This is 
evidenced by multiple carcinogenic agents that exert their 
effects via the DUB pathway. Carcinogenic properties of 
nickel compounds have been attributed to the increased 
ubiquitination of H2A and H2B [84]. However, nickel 
compounds do not affect histone ubiquitination directly 
but rather inhibit the DUBs responsible for reversing 
this process, as such increasing the pool of ubiquitinated 
histones. As a consequence, targeting DUBs might prove 
to be a valid strategy for developing novel anti-cancer 
therapeutics (Table 2). 
Targeting DUBs as an anti-tumourigenic therapeutic 
strategy has its proof of principle in the use of bortezomib, 
a broad range inhibitor of the ubiquitin proteasome 
system, in multiple melanoma treatment [85]. This 
strategy is however limited by the lack of specificity of 
bortezomib which results in toxicity. Targeting individual 
DUBs that play a role in particular cancers is predicted 
to be a much better strategy. However, targeting single 
DUBs is a very complex challenge due to the high levels 
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of homology, particularly between the catalytically active 
domains, and promiscuity. Most DUBs target multiple 
proteins and additionally many of the DUB targets can 
be deubiquitinated by more than one DUB. The same 
DUB can target proteins from the same pathway that exert 
opposing effects, for example Usp7 can deubiquitinate 
both p53 and its E3 ligase MDM2 depending on 
the circumstances. In this context broad spectrum 
inhibitors targeting closely related families of DUBs 
that deubiquitinate the same substrates might in fact be a 
valuable strategy.
As mentioned previously multiple DUBs rely 
on co-factors, such as WD40 proteins, for their activity 
(Table 3), [86], [7]. This poses a very exciting drug design 
opportunity and offers a chance for developing much more 
specific agents when the binding of two proteins rather 
than a conserved active domain of one of them is being 
targeted. As previously discussed, Usp1 is responsible 
for DNA damage response pathway regulation and its 
activity is dependent on binding to its cofactor, Uaf-1. 
This allowed for the identification of more specific agents 
targeting the Usp1 protein’s interaction with Uaf-1 rather 
than Usp1 directly, thus circumventing the potential 
issue of sequence homology and conserved domains 
within similar DUBs. Three Usp1 inhibitors explored 
this strategy, Pimozide [87], ML323 [88], [89], [90] and 
GW7647 [87] each targeting the Usp1-Uaf-1 complex in a 
non-competitive manner. Usp1 known targets include the 
Fanconi anaemia complex proteins, FANC1 and FANCD2, 
PCNA and the inhibitor of DNA binding (ID) transcription 
factors [87]. As Usp1-null mice have been shown to be 
hypersensitive to DNA damage it is likely that targeting 
Usp1 could increase the sensitivity of cancer cells to DNA 
damaging agents [66]. Multiple Usp1 inhibitors have been 
identified via both compound library screening and drug 
development programs. Therapeutic inhibition of Usp1 
was previously reported to re-sensitise cisplatin-resistant 
non-small-cell lung cancer cells to the drug [87]. This 
result was confirmed by an observed increase in the mono-
ubiquitination of PCNA and FANCD2 upon Pimozide 
treatment which indicated successful targeting of Usp1. 
Later reports supported this observation with the ML323 
compound decreasing the cells ability to repair the DNA 
damage and potentiating the effects of cisplatin [88]. The 
authors proposed synthetic lethality as an explanation 
for this observation; because the DNA damage repair 
table 2: currently available agents aimed at dubs discussed in this review
dub compound other targeted dubs reference
Usp1
Pimozide
ML323
SJB2-043 and SJB3-019A 
GW7647
Usp2, Usp5, Usp7, Usp8, Usp46
-
-
-
[87]
[88], [89], [90]
[91]
[87]
Usp7
HBX 19,818 and  HBX 28,258 
P5091 and P22077
Pimozide
Usp47
-
Usp1, Usp2, Usp5, Usp8, Usp46
[93]
[95], [96], [97]
[87]
Usp10 Spautin-1 Usp13 [77]
Usp14 b-AP15AC17
UCHL5
UCHL5
[98]
[99]
Usp46 Pimozide Usp1, Usp2, Usp5, Usp7, Usp8 [87]
table 3: list of dubs discussed in this review that rely on binding to Wd40 proteins
dub Wd40 cellular processes
Usp1 WDR48 (Uaf-1) DNA damage response, Fanconi anaemia pathway, homologous recombination, cellular differentiation and Akt signalling
Usp3 WDTC1 DNA repair and cell cycle progression
Usp7 BUB3, WDR21A, RAE1 Gene expression, protein stability, cell cycle progression and proliferation
Usp12 WDR20, WDR26, WDR48, WDR77, DMWD Transcription, Notch signalling and Akt signalling
Usp22 TAF5L Gene expression, protein stability, proliferation and cell cycle progression
Usp42 WDR18 Transcription, stress response and cell-cycle progression. When fused to RUNX1 it is involved in pathogenesis of acute leukaemia
Usp44 TBL2 DNA repair, cell cycle progression and differentiation
Usp46 WDR20, WDR26, WDR48, WDR77, DMWD Transcription, nervous system development and Akt signalling
Usp49 COPA Gene expression and pre-mRNA processing
Usp50 PRPF4 Cell cycle progression
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pathway is inhibited upon Usp1 targeting then damage 
induced by cisplatin is not being repaired by the cells, 
consequently resulting in cell death. More recently 
developed compounds SJB2-043 and SJB3-019A inhibited 
the salvaging of ID1, ID2, ID3, FANC1 and FANCD2 
proteins by Usp1 from proteosomal degradation and as a 
result caused an increase in cell death and sensitisation to 
DNA damaging agents [91]. 
Usp7 is one of the most extensively researched 
DUBs due to its role in regulating multiple key proteins 
including p53, MDM2, PTEN, FOXO, the polycomb 
complex and histones [92]. During cancer development, 
Usp7 plays an oncogenic role as it promotes cellular 
survival. Most recent attempts at targeting Usp7 include 
development of P5091, HBX 19,818 and HBX 28,258 
inhibitors [93]. All of these compounds were shown to 
abrogate the effects of Usp7 on p53, they also inhibit 
the enhanced tumourigenicity of claspin caused by Usp7 
activity and increase apoptosis in cancer cells [94]. 
Promising data arose from the application of P5091 and its 
second-generation derivative P22077 in an investigation 
where both compounds were capable of increasing 
survival when used as single agents in a xenograft study. 
Additionally, when combined with standard treatments 
synergistic effects and re-sensitisation were observed 
for both compounds in multiple melanoma [95] and 
neuroblastoma [96], respectively. These results are very 
promising as resistance is one of the major challenges 
of present cancer management. As such, developing 
compounds focussed upstream of the present therapeutic 
targets could help to both avoid developing future 
resistance and also allow to re-sensitise patients resistant 
to the available DNA damaging agents by exploring 
synthetic lethality and combining them with inhibitors of 
DUBs responsible for DNA damage repair.
conclusIons And FuturE prospEcts
Discoveries over recent years clearly indicate that 
ubiquitination and deubiquitination regulate cellular 
homeostasis and as a result deregulation of these processes 
can promote cancer development and progression. DUBs 
can affect carcinogenesis through multiple cellular 
pathways with epigenetics being the main example. 
Deubiquitination of histones, transcription factors and 
their co-factors plays a major role in regulating epigenetics 
by DUBs. As a result DUBs could be valuable therapeutic 
targets in oncology. Although this field is still relatively 
novel, recent advances indicate that targeting DUBs could 
be an efficient strategy. Novel inhibitors aimed at both 
Usp1 and Usp7 have been shown to re-sensitise cells to 
known therapeutic agents and to have a therapeutic effect 
when used independently in both the cellular setting 
and in some xenograft models. DUBs might present a 
challenge for compound design as their active domains 
are often conserved and many of them are Cys-dependent 
making targeting more complex. Recently, Usp1 inhibitors 
have been discovered which inhibit Usp1 by targeting its 
interaction with Uaf-1, a protein binding partner required 
for Usp1’s enzymatic activity, rather than by targeting the 
active domain directly. This is a very exciting direction 
which could offer a solution to DUB inhibitors design 
providing both specificity and decreased toxicity. Multiple 
DUBs rely on binding to other proteins for their activity 
and stability and many of those interacting partners are 
WD40 proteins just like Uaf-1 (Table 3), it does however 
remain to be established if this strategy will prove 
therapeutically advantageous.
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